Table 3.

Immune-related responses*

	All treated patients N=50	Progressed on prior anti-PD-1 therapy n=33	No prior anti-PD-1 therapy n=17
Objective response rate, % (95% CI)	30 (18 to 45)	21 (9 to 39)	47 (23 to 72)
Complete response, n (%)	5 (10)	2 (6)	3 (18)
Partial response, n (%)	10 (20)	5 (15)	5 (29)
Stable disease, n (%)	17 (34)	15 (45)	2 (12)
Progressive disease, n (%)	16 (32)	11 (33)	5 (29)
Not evaluable, n (%)	2 (4)	0	2 (12)
Time to initial response, median (range), mo	3.4 (0.7‒5.1)	3.5 (3.2‒5.1)	3.4 (0.7‒3.4)
Disease control rate†, n (%)	32 (64)	22 (67)	10 (59)
Durable response rate‡, % (95% CI)	14 (6 to 27)	12 (3 to 28)	18 (4 to 43)
Duration of response
Median (95% CI), months	8.8 (5.9 to 8.8)	8.8 (5.9 to 8.8)	NR (4.9 to NR)
≥6 months, %	81	80	86

*Data analyzed in the safety analysis set; responses are based on investigator assessment per immune-related response criteria.

†Complete response+partial response+stable disease.

‡Response lasting ≥6 months.

anti-PD-1, antiprogrammed death 1; NR, not reached.